Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Year in review

- PMLiVE

COVID-19 linked to long-term neurologic disorders in new US study

Those infected with the virus had a 77% higher risk of developing memory problems versus control groups

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

- PMLiVE

Pfizer to supply 6 million Paxlovid treatments to low- and middle-income countries

Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17...

Impetus Digital

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

- PMLiVE

Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19

The antiviral showed a 17% lower relative risk of death or progression compared to standard of care

- PMLiVE

YouGov survey shows global health systems ‘unfit to cope’ with another pandemic

60% of healthcare professionals agree a lack of financial support leaves health systems vulnerable

Impact of COVID-19 on the Biopsychosocial Model of Health

Dr. Tarry Ahuja, Manager of Program Development in Pharmaceutical Reviews and Senior RWE Advisor at CADTH, explores the impact of COVID-19 on the biopsychosocial model of health, key opportunities and...

Impetus Digital

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose

- PMLiVE

WHO announces new global fund for pandemic prevention and preparedness

Over $1.4bn in financial commitments have already been announced and more are expected in the coming months

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links